Cancer pain: current practice and emerging targets

Published on April 6, 2026

Br J Pharmacol. 2026 Apr 3. doi: 10.1111/bph.70410. Online ahead of print.

ABSTRACT

Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Recent advances in cancer neuroscience have provided novel insights into the neurobiology of cancer pain. The emerging picture of cancer pain is a disorder of aberrant crosstalk between the tumour, the sensory innervation that the tumour creates and the immune cells that these nerves attract. Precision approaches to disrupt this aberrant pain signalling cascade are guided by newly recognized molecular mechanisms. Here, we review the current practice of cancer pain management and the emerging future of personalized, mechanism-driven pain therapy in oncology.

PMID:41933501 | DOI:10.1111/bph.70410

Continue reading on website
Other news

Implementation of Changes for Basic Experimental Studies with Humans

April 6, 2026
Notice NOT-OD-26-067 from the NIH Guide for Grants and Contracts

The vagus nerve activated by inflammation co-transmits acute visceral pain via the NTS-PVN pathway

April 6, 2026
Brain Behav Immun. 2026 Mar 31:106551. doi: 10.1016/j.bbi.2026.106551. Online ahead of print.ABSTRACTBACKGROUND: Acute pancreatitis (AP) induces visceral pain through inflammation and mechanical stress, yet current treatments remain inadequate. This therapeutic limitation reflects our limited knowledge of how nociceptive signals are transmitted from peripheral visceral afferents to central neural